A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Phase 1 Completed 40 enrolled Immunobrain Checkpoint Alzheimer's Association · collab National Institute on Aging (NIA) · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled first-in-human, Phase 1, safety, tolerability, pharmacokinetic (PK) and preliminary exploratory activity study of escalating multiple intravenous (IV) doses of IBC-Ab002 in persons with early Alzheimer's disease. The study will have both Single- and Multiple-Ascending Dose components.

Timeline

Start: 2023-02-23
Primary completion: 2025-12-16
Completion: 2025-12-16

Outcome

Met primary endpoint

paper Treatment was well tolerated, with no treatment-related serious adverse events or evidence of amyloid-related imaging abnormalities. PMID 42458012 ↗

Publications

Croese T, Mummery CJ, Bregman N, Bracha D, Baruch K, Kertser A, Raveh S, Shochat E, Schwartz M. Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial. Nat Med. 2026 Jul 15. doi: 10.1038/s41591-026-04547-8. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IBC-Ab002	Monoclonal antibody	—	Intravenous